Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COBALT: OZURDEX in BRVO-associated Macular Edema
NCT01903720Phase 4Completed
- Sponsor
- Allergan
- Start
- Jul 2013
- Primary completion
- Sep 2014
- Modality
- Implantable Devices, Implantable Hydrogels, Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of ozurdex in macular edema, branch retinal vein occlusion (BRVO), sponsored by Allergan. Started Jul 2013; status: completed.
02
Drugs
ozurdex
03
Conditions
macular edemabranch retinal vein occlusion (BRVO)
Beyond the preview
Go deeper on NCT01903720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01903720.